LGND

LigandD

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

Operating peers and competitors

Source-backed product markets and frozen research comparisons. Valuation comparators remain in the existing peer table.

Loading market evidence...

Research comparisons do not establish forecast usefulness or trading returns.

Compare shared product markets

Membership only; no portfolio weights or estimated losses.

Peers tracked

U.S. public peers

Grade Position

In line

vs peer average

LGND vs peer average

54/100

LGND vs. peer average (D vs. D)

Grade spread

B 1 · C 1 · D 2 · F 5

Graded peers loaded

Coverage

9 graded

90% of tracked

Peer overview

RPRX is the first available peer comparator.

Royalty Pharma remains the clearest public model peer for diversified biopharma royalty cash-flow valuation, even though it operates at much larger scale.

✓Peer source comes from the stored AI memo or peer model

✓Grades and factor rows use RankAlpha API data when available

✓Missing peer scores remain blank instead of being estimated

✓Side-by-side comparison keeps the data contract visible

Top peerRPRXRoyalty

LGND

Ligand

RPRX

Royalty

Grade

Momentum

Value

Sentiment

Setup Bias

Net —

Market Cap

Posture

Defensive

Open Side-by-Side Comparison Compare top peers (up to 3)

Grade position vs RPRX

LGND / RPRX

Grade Position

In line

LGND vs. peer average (D vs. D)

54/100

Momentum

LGND

Value

RPRX

Sentiment

RPRX

Rotation landscape

Peers ranked by the order returned from the peer source, with grades from the API.

Rank

Ticker

Company

Grade

Grade score

vs LGND

RPRX

40/100

Even

XOMA

RYTM

Rhythm Pharmaceuticals Inc Common

20/100

-1

IOVA

Iovance Biotherapeutics Inc Common

20/100

-1

GRAL

GRAIL Inc Common

20/100

-1

RPRX is the first peer returned for this comparison set.